A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar Depression

Trial Profile

A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar Depression

Completed
Phase of Trial: Phase II

Latest Information Update: 04 May 2018

At a glance

  • Drugs Cariprazine (Primary)
  • Indications Bipolar I disorders
  • Focus Therapeutic Use
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 03 Apr 2018 According to the Allergan media release, company plans to include data from this and other two pivotal trials (700267785 and 700267733) in the Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2018.
    • 06 Nov 2015 Results published online in the American Journal of Psychiatry.
    • 20 May 2015 Results presented at the 168th Annual Meeting of the American Psychiatric Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top